PROTHELIA INCORPORATED

Prothelia is developing recombinant human Laminin-111 (rhLAM-111) for treatment of congenital muscular dystrophy type 1A. This form of muscular dystrophy is also referred to as MDC1A, Merosin deficiency or LAMA2 deficiency.

Website: prothelia.com

Employees: 10 - 19

HQ: 508-561-9298

Location: Milford, MA, US

Revenue: 1 - 2.5 Million

N/A

PROTHELIA INCORPORATED Technologies

Email Providers

Outlook

Load Balancers

Nginx

CMS

WordPress.org

Fonts

Google Font API

Other

Mobile Friendly

Online Video Platforms

Vimeo

View All Technologies Used At PROTHELIA INCORPORATED

Similar companies to PROTHELIA INCORPORATED

Tidal Therapeutics Boston Biochem Inc. Amagma Therapeutics nanoCLEAN Decontamination Services Venture Forward Psy Therapeutics Kephera Diagnostics PIC Therapeutics RAN Biotechnologies Directed Genomics Related Sciences QLB Biotherapeutics Symbiotix Biotherapies, Inc. Travera bioX Corval Poxy Clinical Raqia Therapeutics, Inc. Immunovia, Inc. ISPE Boston Area Chapter

Contacting PROTHELIA INCORPORATED: Connect with Executives and Employees

Get in Touch with PROTHELIA INCORPORATED Executives and Employees

Connecting with PROTHELIA INCORPORATED's Executives and Workforce

Accessing Contact Information for PROTHELIA INCORPORATED Executives

Connecting with PROTHELIA INCORPORATED: Reach Out to Their Team

Discover How to Contact PROTHELIA INCORPORATED Executives and Staff

Looking to connect with PROTHELIA INCORPORATED executives or employees?

Seeking to Get in Touch with PROTHELIA INCORPORATED Executives or Staff?

Want to Reach Out to PROTHELIA INCORPORATED Executives or Team Members?

In Search of Contact Details for PROTHELIA INCORPORATED Professionals?

Connecting with PROTHELIA INCORPORATED: Contacting Executives and Staff

Browse companies

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z